Protein Summary
Involved in endocytosis and intracellular vesicle trafficking, both during interphase and at the end of mitosis. Required for efficient progress through mitosis and cytokinesis. Required for normal formation of the cleavage furrow at the end of mitosis. Plays a role in endocytosis via clathrin-coated pits, but also clathrin-independent, actin-dependent fluid-phase endocytosis. Plays a role in macropinocytosis. Promotes internalization of TNFR. Promotes degradation of EGFR after EGF signaling. Stimulates the GTPase activity of DNM1. Promotes DNM1 oligomerization. Promotes activation of the Arp2/3 complex by WASL, and thereby plays a role in the reorganization of the F-actin cytoskeleton. Binds to membranes enriched in phosphatidylinositol 4,5-bisphosphate and promotes membrane tubulation. Has lower affinity for membranes enriched in phosphatidylinositol 3-phosphate. This gene encodes a member of the sorting nexin family. Members of this family contain a phosphoinositide binding domain, ...more
- ENST00000392185
- ENSP00000376024
- ENSG00000130340
- SH3PX1
- SH3PXD3A
- SDP1
- WISP
- SH3PX1
- SH3PXD3A
Most Knowledge About | Knowledge Value
(0 to 1 scale) | ||
---|---|---|---|
virus perturbation | 0.94 | ||
kinase perturbation | 0.84 | ||
disease perturbation | 0.83 | ||
microRNA | 0.79 | ||
biological process | 0.75 | ||
Protein Classes
IDG Development Level Summary
These are targets about which virtually nothing is known. They do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 87.82 (req: < 5)
Gene RIFs: 32 (req: <= 3)
Antibodies: 345 (req: <= 50)
These targets do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 87.82 (req: >= 5)
Gene RIFs: 32 (req: > 3)
Antibodies: 345 (req: > 50)
- OR - satisfy the following criterion:
Gene Ontology Terms: 20
Target has at least one ChEMBL compound with an activity cutoff of < 30 nM - AND - satisfies the preceding conditions
Active Ligand: 0
Target has at least one approved drug - AND - satisfies the preceding conditions
Active Drug: 0